eMedicine Specialties > Neurology > Seizures and Epilepsy

Generalized Tonic-Clonic Seizures: Differential Diagnoses & Workup

Author: David Y Ko, MD, Associate Professor, Department of Neurology, University of Southern California Keck School of Medicine
Coauthor(s): Soma Sahai-Srivastava, MD, Director of Neurology Ambulatory Care Services, LAC and USC Medical Center; Assistant Professor, Department of Neurology, University of Southern California
Contributor Information and Disclosures

Updated: May 6, 2009

Differential Diagnoses

Complex Partial Seizures
Migraine Headache
Confusional States and Acute Memory Disorders
Migraine Headache: Neuro-Ophthalmic Perspective
Dizziness, Vertigo, and Imbalance
Migraine Headache: Pediatric Perspective
Driving and Neurological Disease
Migraine Variants
Epilepsy and the Autonomic Nervous System
Narcolepsy
Epilepsy in Adults with Mental Retardation
Seizures and Epilepsy: Overview and Classification
Epilepsy in Children with Mental Retardation
Somnambulism (Sleep Walking)
Febrile Seizures
Status Epilepticus
Frontal Lobe Epilepsy
Syncope and Related Paroxysmal Spells
Herpes Simplex Encephalitis
Viral Encephalitis

Other Problems to Be Considered

Hyperventilation and electrolyte imbalances
Prolonged QT syndrome and other arrhythmias
Dystonias including nocturnal paroxysmal dystonias
Paroxysmal dyskinesias2
Encephalopathies and metabolic disorders
Pseudoepileptic seizures
Nocturnal paroxysmal events (eg, sleep apnea, night terrors)2
Paroxysmal abnormalities of tone (eg, opisthotonic posturing and clonus)
In infants, apneic syndromes including gastroesophageal reflux and jitteriness of the newborn
In toddlers and young school-aged children, simple faints and breath-holding spells2

Workup

Laboratory Studies

  • Plasma prolactin levels, if investigated within 10-20 minutes of a generalized tonic-clonic seizure, are elevated 5-30 times the baseline values. The plasma prolactin level is a useful diagnostic tool to exclude pseudoseizures if the seizure looks like a tonic-clonic seizure. Prolactin level may not be elevated in absence and myoclonic seizures and in simple and brief complex partial seizures.
  • Serum adrenocorticotropic hormone (ACTH), cortisol, vasopressin, growth hormone, and beta-endorphin levels also are increased postictally but for a very brief duration; therefore, they are not useful clinically.
  • In 15% of patients, especially after a prolonged seizure, cerebrospinal fluid (CSF) pleocytosis may be found (commonly 10 cells/mm3 and rarely as many as 50 cells/mm3).
  • Metabolic acidosis and elevated levels of serum lactate and creatine kinase are common findings after a seizure.

Imaging Studies

  • Imaging studies may not be necessary in a small subgroup of patients with a clear history of myoclonic epilepsy and absence, with classic 4- to 5-Hz polyspike and wave and EEG from which the diagnosis of a generalized epilepsy syndrome like juvenile myoclonic epilepsy can be made with reasonable certainty (along with other supporting evidence, nonfocal neurologic examination findings and a family history of seizures), because the likelihood of finding an abnormality on imaging is very low. In practice, however, complete certainty is not possible; therefore, brain imaging is the next step in the workup of patients with epilepsy.
  • An abnormality on CT scans is rare in patients with primary generalized tonic-clonic seizures. Because CT will not detect most types of congenital structural brain abnormalities, MRI is the imaging modality of choice.
  • Neuronal migration disorders that may be diagnosed on MRI include lissencephaly, pachygyria, band or laminar heterotopia, subependymal heterotopias, focal cortical dysplasia polymicrogyria, focal subependymal heterotopias, and schizencephaly.
  • Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) scans have no role in the workup of generalized tonic-clonic seizures, except if the diagnosis of primary generalized seizure itself is in doubt.

Other Tests

  • Interictal EEG
    • The awake EEG of patients with generalized tonic-clonic seizure is often normal. Interictal abnormalities include spikes, sharp waves, polyspikes, and polyspike or spike-and-wave complexes.
    • Hyperventilation, photic stimulation, and sleep-deprived EEG can increase the likelihood of finding an abnormality on EEG.
    • Paroxysmal frontal intermittent rhythmic delta activity (FIRDA) may be found in some patients, especially those with a history of absences, but this is a nonspecific abnormality that is not considered epileptiform.
    • Certain specific interictal EEG patterns can be distinctive of generalized epilepsy syndromes: (1) generalized bilaterally synchronous 3-Hz spike-and-wave complexes are associated with typical absence attacks; (2) fast spike-and-wave activity at 4-5 Hz is associated most often with generalized tonic-clonic seizures; (3) polyspikes or polyspike and slow-wave complexes usually are seen with juvenile myoclonic epilepsy.
  • Ictal EEG
    • The tonic phase of convulsion is characterized by progressively higher amplitude and lower frequency discharge pattern observed simultaneously in both cortical hemispheres, reaching a maximum of 10 Hz.
    • This then becomes slower and mixed with bilateral high-amplitude spikes and a progressively greater amount of high-amplitude rhythmic delta activity. These are slow, developing progressively into repetitive complexes of high-amplitude spike-and-slow-wave activity in the clonic phase.
  • Postictal EEG: The postictal EEG may be isoelectric or may show diffuse, very low-amplitude, slow delta activity. This corresponds to sustained hyperpolarization.
  • Patients with generalized tonic-clonic seizures and idiopathic generalized epilepsy typically have no evidence of any localized, regional, or diffuse brain abnormality on history, physical, or neurologic examination; clinical laboratory testing; or imaging studies.

More on Generalized Tonic-Clonic Seizures

Overview: Generalized Tonic-Clonic Seizures
Differential Diagnoses & Workup: Generalized Tonic-Clonic Seizures
Treatment & Medication: Generalized Tonic-Clonic Seizures
Follow-up: Generalized Tonic-Clonic Seizures
References

References

  1. Walczak TS, Leppik IE, D'Amelio M, Rarick J, So E, Ahman P, et al. Incidence and risk factors in sudden unexpected death in epilepsy: a prospective cohort study. Neurology. Feb 27 2001;56(4):519-25. [Medline].

  2. Morrell MJ. Differential diagnosis of seizures. Neurol Clin. Nov 1993;11(4):737-54. [Medline].

  3. [Best Evidence] Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. Mar 24 2007;369(9566):1016-26. [Medline].

  4. Peters DH, Sorkin EM. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs. May 1993;45(5):760-87. [Medline].

  5. Kluger G, Bauer B. Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy). Neuropsychiatr Dis Treat. Feb 2007;3(1):3-11. [Medline].

  6. [Best Evidence] Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. May 20 2008;70(21):1950-8. [Medline].

  7. Epilepsy and other seizure disorders. In: Ropper AH and Samuels M, eds. Adams and Victor's Principles of Neurology. 9th ed. New York: McGraw-Hill; 2009.

  8. Clark S, Wilson WA. Mechanisms of epileptogenesis. Adv Neurol. 1999;79:607-30. [Medline].

  9. Engel J, Pedley TA. Generalized convulsive seizures. In: Engel J, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. 3 vol. Philadelphia: Lippincott-Raven; 1997:2417-2426.

  10. Kerrigan JF, Fisher RS. Recurrent generalized and partial epilepsy. In: Current Therapy in Neurologic Disease. Philadelphia: BC Decker; 1997:52-53.

Further Reading

Keywords

partial seizures, tonic-clonic activity, tonic-clonic seizures, generalized tonic-clonic seizure, GTCS, epilepsy, generalized seizures, seizure treatment, focal seizures, localization-related seizures, sudden death in epilepsy, SUDEP, generalized convulsive seizures, grand mal seizure

Contributor Information and Disclosures

Author

David Y Ko, MD, Associate Professor, Department of Neurology, University of Southern California Keck School of Medicine
David Y Ko, MD is a member of the following medical societies: American Academy of Neurology, American Clinical Neurophysiology Society, American Medical Association, and California Medical Association
Disclosure: Pfizer Honoraria Speaking and teaching; UCB Grant/research funds clinical trials; Johnson and Johnson Grant/research funds clinical trials

Coauthor(s)

Soma Sahai-Srivastava, MD, Director of Neurology Ambulatory Care Services, LAC and USC Medical Center; Assistant Professor, Department of Neurology, University of Southern California
Soma Sahai-Srivastava, MD is a member of the following medical societies: American Academy of Neurology, American Headache Society, and American Medical Association
Disclosure: Nothing to disclose.

Medical Editor

Ramon Diaz-Arrastia, MD, PhD, Assistant Professor, Department of Neurology, Comprehensive Epilepsy Center, University of Texas Southwestern
Ramon Diaz-Arrastia, MD, PhD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, New York Academy of Sciences, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Jose E Cavazos, MD, PhD, FAAN, Associate Professor with Tenure, Departments of Neurology, Pharmacology, and Physiology, University of Texas Health Science Center at San Antonio; Co-Director, South Texas Comprehensive Epilepsy Center; Director of the Epilepsy Center, Audie L Murphy Veterans Affairs Medical Center
Jose E Cavazos, MD, PhD, FAAN is a member of the following medical societies: American Academy of Neurology, American Clinical Neurophysiology Society, American Epilepsy Society, and Society for Neuroscience
Disclosure: Glaxo-SmithKline Honoraria Consulting; Ortho-McNeil Neurologics Honoraria Consulting; UCB Pharma Honoraria Consulting

CME Editor

Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital
Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association
Disclosure: Nothing to disclose.

Chief Editor

Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital
Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.